adalimumab

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial
Rosaria Talarico, Nazzareno Italiano, Giacomo Emmi, Matteo Piga, Luca Cantarini, Irene Mattioli, Alberto Floris, Stefano Gentileschi, Federica Di Cianni, Maria Letizia Urban, Emanuele Chiara, Diana Marinello, Alessandra Del Bianco, Michele Figus, Chiara Posarelli, Claudia Fabiani, Sabrina Vagnani, Gianni Andreozzi, Valentina Lorenzoni, Giuseppe Turchetti, Alberto Cauli, Lorenzo Emmi, Carlo Salvarani, Ornella Della Casa Alberighi, Stefano Bombardieri, Marta Mosca

Annals of the Rheumatic Diseases Oct 2024, ard-2024-226113; DOI: 10.1136/ard-2024-226113
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial
Hiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, Hiroaki Taguchi, Chang-Fu Kuo, Kichul Shin, Shintaro Hirata, Yutaka Okano, Shinji Sato, Hidekata Yasuoka, Masataka Kuwana, Tomonori Ishii, Hideto Kameda, Toshihisa Kojima, Yurie Nishi, Masahiko Mori, Hideaki Miyagishi, Genta Toshima, Yasunori Sato, Wen-Chan Tsai, Tsutomu Takeuchi, Yuko Kaneko

Annals of the Rheumatic Diseases Oct 2024, ard-2024-226350; DOI: 10.1136/ard-2024-226350
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
Marcin Stajszczyk, Izabela Obarska, Slawomir Jeka, Bogdan Batko

Annals of the Rheumatic Diseases Sep 2023, 82 (9) 1171-1180; DOI: 10.1136/ard-2022-223696
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
Chuan Fu Yap, Nisha Nair, Annick de Vries, Floris C Loeff, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Anne Barton, Darren Plant

Annals of the Rheumatic Diseases Feb 2024, 83 (2) 263-265; DOI: 10.1136/ard-2023-223955
Time to treat the climate and nature crisis as one indivisible global health emergency
Chris Zielinski

Annals of the Rheumatic Diseases Dec 2023, 82 (12) 1506-1507; DOI: 10.1136/ard-2023-225126
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Lea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian

Annals of the Rheumatic Diseases Feb 2023, 82 (2) 182-188; DOI: 10.1136/ard-2022-222824
Neuroinflammatory events after anti-TNFα therapy
Evripidis Kaltsonoudis, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos

Annals of the Rheumatic Diseases May 2022, 81 (5) e73; DOI: 10.1136/annrheumdis-2020-217723
Response to: Where are the women ‘Heroes and Pillars of Rheumatology’?
Josef S Smolen

Annals of the Rheumatic Diseases Aug 2023, 82 (8) e200; DOI: 10.1136/annrheumdis-2021-222050
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 889-894; DOI: 10.1136/ard.2005.043166
Thank you to our reviewers 2022
Annals of the Rheumatic Diseases Apr 2023, 82 (4) 583-584; DOI: 10.1136/ard-2023-223894

Main menu

adalimumab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

adalimumab

Pages